Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Syngeneic tobacco carcinogen–induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden
Laura P. Stabile, Vinod Kumar, Autumn Gaither-Davis, Eric H. Huang, Frank P. Vendetti, Princey Devadassan, Sanja Dacic, Riyue Bao, Richard A. Steinman, Timothy F. Burns, Christopher J. Bakkenist
Laura P. Stabile, Vinod Kumar, Autumn Gaither-Davis, Eric H. Huang, Frank P. Vendetti, Princey Devadassan, Sanja Dacic, Riyue Bao, Richard A. Steinman, Timothy F. Burns, Christopher J. Bakkenist
View: Text | PDF
Resource and Technical Advance Oncology

Syngeneic tobacco carcinogen–induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden

  • Text
  • PDF
Abstract

Human lung adenocarcinoma (LUAD) in current or former smokers exhibits a high tumor mutational burden (TMB) and distinct mutational signatures. Syngeneic mouse models of clinically relevant smoking-related LUAD are lacking. We established and characterized a tobacco-associated, transplantable murine LUAD cell line, designated FVBW-17, from a LUAD induced by the tobacco carcinogen 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone in the FVB/N mouse strain. Whole-exome sequencing of FVBW-17 cells identified tobacco-associated KrasG12D and Trp53 mutations and a similar mutation profile to that of classic alkylating agents with a TMB greater than 500. FVBW-17 cells transplanted subcutaneously, via tail vein, and orthotopically generated tumors that were histologically similar to human LUAD in FVB/N mice. FVBW-17 tumors expressed programmed death ligand 1 (PD-L1), were infiltrated with CD8+ T cells, and were responsive to anti–PD-L1 therapy. FVBW-17 cells were also engineered to express green fluorescent protein and luciferase to facilitate detection and quantification of tumor growth. Distant metastases to lung, spleen, liver, and kidney were observed from subcutaneously transplanted tumors. This potentially novel cell line is a robust representation of human smoking-related LUAD biology and provides a much needed preclinical model in which to test promising new agents and combinations, including immune-based therapies.

Authors

Laura P. Stabile, Vinod Kumar, Autumn Gaither-Davis, Eric H. Huang, Frank P. Vendetti, Princey Devadassan, Sanja Dacic, Riyue Bao, Richard A. Steinman, Timothy F. Burns, Christopher J. Bakkenist

×

Figure 2

Somatic mutation profile of FVBW-17 represents a classic alkylating signature with validated Kras and Trp53 mutations.

Options: View larger image (or click on image) Download as PowerPoint
Somatic mutation profile of FVBW-17 represents a classic alkylating sign...
(A) Pattern of the FVBW-17 mutation signature associated with NNK using a 96-substitution classification. Variants were grouped by the trinucleotide sequence context centered at the mutated base shown on the x axis. The percentage of variants carrying the trinucleotide sequence context out of the whole mouse genome is shown on the y axis. (B) Comparison of FVBW-17 TMB to that of primary tumors from TCGA LUAD patients grouped by tobacco smoking history. Each short red horizontal line indicates the TMB value of each FVBW-17 line (median = 570). The numbers on the right show the TMBs for each of the 4 lines. TMB was defined as the total number of somatic mutations predicted to affect protein sequences (non-synonymous somatic mutations, NSSMs). n = 471 samples shown. Each shorter black horizontal line represents 1 tumor. Longer black horizontal line represents median of TMB in each group. (C) Distribution of different variant types that affect the coding regions of the genome. Ten categories are shown based on exonic function annotation of each variant (synonymous mutations included), with numbers from each category shown in between parentheses. (D) Distribution of somatic VAFs across coding variants from C. The VAFs of Trp53 P275S and Kras G12D are shown as red horizontal lines. n = 872 coding variants shown. Each shorter black horizontal line represents 1 variant. Longer black horizontal line represents median of VAF. (E) Lollipop plot showing the location of Trp53 and Kras somatic mutations in the protein domain. Trp53 green box: transactivation domain. Trp53 red box: DNA binding domain. Trp53 blue box: tetramerization domain. Kras green box: Ras domain.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts